-+ 0.00%
-+ 0.00%
-+ 0.00%

AstraZeneca presents Phase III EMERALD-3 data for Imfinzi-Imjudo in liver cancer at ASCO 2026

PUBT·05/22/2026 06:11:16
Listen to the news
AstraZeneca presents Phase III EMERALD-3 data for Imfinzi-Imjudo in liver cancer at ASCO 2026
  • AstraZeneca flagged multiple late-stage readouts for ASCO 2026, with Phase III data set for future presentation between May 29 and June 2.
  • The most material update is a late-breaking EMERALD-3 presentation on Imfinzi with Imjudo in unresectable liver cancer, aimed at moving the immunotherapy regimen into earlier-stage treatment settings.
  • In rare disease, Phase III CARES results on anselamimab in light chain amyloidosis are scheduled to show a clinically meaningful benefit, supporting a potential first-in-class therapy and a new commercial opportunity beyond oncology.
  • Breast cancer updates are also due from Phase III SERENA-6, DESTINY-Breast09, and TROPION-Breast02, reinforcing the company’s strategy to extend its franchise across major metastatic subtypes.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AstraZeneca plc published the original content used to generate this news brief on May 22, 2026, and is solely responsible for the information contained therein.